Inactive Instrument

News ChemoCentryx, Inc.

Equities

CCXI

US16383L1061

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

ChemoCentryx, Inc.(NasdaqGS:CCXI) dropped from S&P Global BMI Index	22-10-24	CI
ChemoCentryx, Inc.(NasdaqGS:CCXI) dropped from S&P TMI Index	22-10-24	CI
ChemoCentryx, Inc.(NasdaqGS:CCXI) dropped from S&P Biotechnology Select Industry Index	22-10-24	CI
Amgen Completes ChemoCentryx Acquisition	22-10-20	MT
CHEMOCENTRYX, INC. : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	22-10-20	AQ
Chemocentryx, Inc. Announces Executive Changes	22-10-20	CI
AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX	22-10-20	PR
ChemoCentryx, Inc.(NasdaqGS:CCXI) dropped from NASDAQ Composite Index	22-10-20	CI
Amgen Inc. completed the acquisition of ChemoCentryx, Inc. from a group of shareholders.	22-10-19	CI
ChemoCentryx, Inc.(NasdaqGS:CCXI) dropped from NASDAQ Biotechnology Index	22-10-19	CI
CHEMOCENTRYX, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	22-10-18	AQ
ChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and American College of Rheumatology Annual Meetings	22-10-17	GL
ChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and American College of Rheumatology Annual Meetings	22-10-17	GL
ChemoCentryx Announces Upcoming Presentations for Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting	22-10-05	GL
Swissmedic OKs ChemoCentryx's Combo Therapy For Rare Blood Vessel Disease	22-09-27	MT
CHEMOCENTRYX, INC. : Other Events (form 8-K)	22-09-20	AQ
ChemoCentryx Announces TAVNEOS (avacopan) Presentations at Upcoming Medical Conferences	22-08-25	AQ
ChemoCentryx Announces TAVNEOS® (avacopan) Presentations at Upcoming Medical Conferences	22-08-24	GL
Insider Sell: Chemocentryx	22-08-18	MT
UK Agency Recommends Tavneos Combo for Treatment of Rare Blood Vessel Disease	22-08-18	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News ChemoCentryx, Inc.

Equities

CCXI

US16383L1061

Summary

Filters